37 CFR 1.835 — Amendment to add or replace a “Sequence Listing XML” in patent applications filed on or after July 1, 2022
Ninth Edition, Revision 01.2024
- (a) Any amendment to a patent application
adding an initial submission of a “Sequence Listing XML” as
required by §
1.831(a)
after
the application filing date must include:
- (1) A “Sequence Listing XML” in
accordance with §§
1.831
through
1.834
, submitted as an XML file:
- (i) Via the USPTO patent electronic filing system; or
- (ii) On a read-only optical disc, in compliance with § 1.52(e) ;
- (2) A request to amend the specification to include an incorporation by reference statement of the material in the “Sequence Listing XML” file, identifying the name of the file, the date of creation, and the size of the file in bytes ( see § 1.77(b)(5)(ii) ), except when submitted to the United States International Preliminary Examining Authority for an international application;
- (3) A statement that indicates the basis for the amendment, with specific references to particular parts of the application as originally filed (specification, claims, drawings) for all sequence data in the “Sequence Listing XML”; and
- (4) A statement that the “Sequence Listing XML” includes no new matter.
- (1) A “Sequence Listing XML” in
accordance with §§
1.831
through
1.834
, submitted as an XML file:
- (b) Any amendment adding to, deleting from,
or replacing sequence information in a “Sequence Listing XML”
submitted as required by §
1.831(a)
must include:
- (1) A replacement “Sequence Listing
XML” in accordance with the requirements of §§
1.831
through
1.834
containing the entire “Sequence Listing XML,” including any
additions, deletions, or replacements of sequence
information, which shall be submitted:
- (i) Via the USPTO patent electronic filing system; or
- (ii) On a read-only optical disc, in compliance with § 1.52(e) , labeled as “REPLACEMENT MM/DD/YYYY” (with the month, day, and year of creation indicated);
- (2) A request to amend the specification to include an incorporation by reference statement of the material in the replacement “Sequence Listing XML” file that identifies the name of the file, the date of creation, and the size of the file in bytes ( see § 1.77(b)(5)(ii) ), except when the replacement “Sequence Listing XML” is submitted to the United States International Preliminary Examining Authority for an international application;
- (3) A statement that identifies the location of all additions, deletions, or replacements of sequence information relative to the replaced “Sequence Listing XML”;
- (4) A statement that indicates the support for the additions, deletions, or replacements of the sequence information, with specific references to particular parts of the application as originally filed (specification, claims, drawings) for all amended sequence data in the replacement “Sequence Listing XML”; and
- (5) A statement that the replacement “Sequence Listing XML” includes no new matter.
- (1) A replacement “Sequence Listing
XML” in accordance with the requirements of §§
1.831
through
1.834
containing the entire “Sequence Listing XML,” including any
additions, deletions, or replacements of sequence
information, which shall be submitted:
- (c) The specification of a complete application, filed on the application filing date, with a “Sequence Listing XML” as required under § 1.831(a) , without an incorporation by reference of the material contained in the “Sequence Listing XML” file, must be amended to include a separate paragraph incorporating by reference the material contained in the “Sequence Listing XML” file, in accordance with § 1.77(b)(5)(ii) , except for international applications.
- (d)
- (1) If any of the requirements of §§ 1.831 through 1.834 are not satisfied in an application under 35 U.S.C. 111(a) or in a national stage application under 35 U.S.C. 371 , the applicant will be notified and given a period of time within which to comply with such requirements in order to prevent abandonment of the application. Subject to paragraph (d)(2) of this section, any amendment to add or replace a “Sequence Listing XML” or add an incorporation by reference of the material contained in the “Sequence Listing XML” in response to a requirement under this paragraph (d)(1) must be submitted in accordance with the requirements of paragraphs (a) through (c) of this section.
- (2) Compliance with paragraphs (a) through (c) of this section is not required for submission of a “Sequence Listing XML” that is solely an English translation of a previously submitted “Sequence Listing XML” that contains non-English values for any language-dependent free text elements (as per § 1.833(b)(3) ). The required submission will be a translated “Sequence Listing XML” in compliance with §§ 1.831 through 1.834 . Updated values for attributes in the root element (§ 1.833(b)(2)(iii) ) or elements of the general information part (§ 1.833(b)(2)(iv) ) are not considered amendments for purposes of complying with paragraphs (a) through (c) of this section.
- (e) If any of the requirements of §§ 1.831 through 1.834 are not satisfied at the time of filing an international application under the PCT, where the application is to be searched by the United States International Searching Authority or examined by the United States International Preliminary Examining Authority, the applicant may be sent a notice necessitating compliance with the requirements within a prescribed time period. Under PCT Rule 13ter , the applicant can provide, in response to such a requirement or otherwise, a sequence listing that is a “Sequence Listing XML” in accordance with § 1.831(a) . The “Sequence Listing XML” must be accompanied by a statement that the information recorded does not go beyond the disclosure in the international application as filed. In response to such a requirement, the late furnishing fee set forth in § 1.445(a)(5) is also required. If the applicant fails to timely provide the required “Sequence Listing XML,” the United States International Searching Authority shall search only to the extent that a meaningful search can be performed without the “Sequence Listing XML,” and the United States International Preliminary Examining Authority shall examine only to the extent that a meaningful examination can be performed without the “Sequence Listing XML.”
- (f) Any appropriate amendments to the “Sequence Listing XML” in a patent ( e.g., by reason of reissue, reexamination, or certificate of correction) must comply with the requirements of paragraph (b) of this section.
[Added 87 FR 30806, May, 20, 2022, effective July 1, 2022]
Cited authority
- 37 CFR 1.831 Requirements for patent applications filed on or after July 1, 2022, having nucleotide and/or amino acid sequence disclosures
- 37 CFR 1.834 Form and format for nucleotide and/ or amino acid sequence submissions as the ‘‘Sequence Listing XML’’ in patent applications filed on or after July 1, 2022
- 37 CFR 11.52 Written discovery
- 37 CFR 1.77 Arrangement of application elements
- 35 U.S.C. 111 Application
- 35 U.S.C. 371 National stage: Commencement
- 37 CFR 1.833 Requirements for a “Sequence Listing XML” for nucleotide and/or amino acid sequences as part of a patent application filed on or after July 1, 2022
- PCT Rule 13 ter Nucleotide and/or Amino Acid Sequence Listings
- 37 CFR 1.445 International application filing, processing and search fees
Cited by
- 1002.02(c) Petitions and Requests Decided by the Technology Center Directors
- 1120 Eighteen-Month Publication of Patent Applications
- 1121 Content of a Patent Application Publication
- 1453 Amendments to Reissue Applications
- 2234 Entry of Amendments
- 2250 Amendment by Patent Owner
- 2401 Introduction
- 2412 The Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures to Include a Sequence Listing in XML file format
- 2412.03 Nucleotides and Amino Acids Included and Excluded From a “Sequence Listing XML”
- 2412.04 Use of Sequence Identifiers to Denote Sequences Disclosed in the Description, Drawings or Claims
- 2413.03 How to Submit the “Sequence Listing XML”
- 2413.05 Presumptions Regarding Compliance
- 2414 Notification of a Failure to Comply with Sequence Listing Requirements and Amendments Relating to “Sequence Listing XML” Files Under 37 CFR 1.835
- 2414.01 Issuance of a Notice Relating to the Requirements For Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures
- 2414.02 Amendment to Add an Initial “Sequence Listing XML” under 37 CFR 1.835(a)
- 2414.03 Amendment Adding to, Deleting from, or Replacing Sequence Information in a “Sequence Listing XML” under 37 CFR 1.835(b)
- 2414.04 Translation of “Sequence Listing XML” is Not an Amended “Sequence Listing XML” under 37 CFR 1.835(b)
- 2414.06 Amendment of a “Sequence Listing XML” in a Patent
- 2415.01 Determining if a “Sequence Listing XML” Must be Submitted
- 2415.03 Improper Submissions of “Sequence Listing” under 1.821(c) When a “Sequence Listing XML” was Required
- 2416 Form Paragraphs
- 2417 Helpful Hints for Sequence Rules Compliance under WIPO Standard ST.26
- 2418 WIPO Sequence Tool
- 2730 Applications Filed on or After May 29, 2000; Grounds for Adjustment
- 2732 Reduction of Period of Adjustment of Patent Term
- 608.01 Specification
- 608.05 “Sequence Listing,” “Large Tables,” or “Computer Program Listing Appendix” Submitted in ASCII Plain Text or a “Sequence Listing XML” Submitted as XML File Text
- 708.02(a) Accelerated Examination
- 714 Amendments, Applicant’s Action
- 37 CFR 1.52 Language, paper, writing, margins, read-only optical disc specifications
- 37 CFR 1.121 Manner of making amendments in applications
- 37 CFR 1.173 Reissue specification, drawings, and amendments
- 37 CFR 1.211 Publication of applications
- 37 CFR 1.530 Statement by patent owner in ex parte reexamination; amendment by patent owner in ex parte or inter partes reexamination; inventorship change in ex parte or inter partes reexamination
- 37 CFR 1.704 Reduction of period of adjustment of patent term
- 37 CFR 1.821 Nucleotide and/or amino acid sequence disclosures in patent applications
- 37 CFR 1.822 Symbols and format to be used for nucleotide and/or amino acid sequence data
- 37 CFR 1.823 Requirements for content of a “Sequence Listing” part of the specification
- 37 CFR 1.824 Form and format for a nucleotide and/or amino acid sequence submissions as an ASCII plain text file
- 37 CFR 1.825 Amendments to add or replace a “Sequence Listing” and CRF copy thereof
- 37 CFR 1.831 Requirements for patent applications filed on or after July 1, 2022, having nucleotide and/or amino acid sequence disclosures